WOCKPHARMA

Wockhardt staged a strong turnaround in FY26, returning to profitability after several years of losses, driven by robust revenue growth and a recovery in its biotech and emerging markets segments. In Q4FY26, the drugmaker posted a net profit of ₹164 crore, compared to a loss of ₹45 crore in the same period last year. This was supported by a 30% year-on-year increase in revenue to ₹965 crore, along with significant margin expansion and strong demand in its insulin-focused biotech portfolio. The improvement in quarterly performance was further aided by higher scale in emerging markets and tighter cost management, even as investments in research and development remained consistent. On the exceptional front, Q4 included a charge of ₹22 crore. For the full year, exceptional items largely balanced out, with gains from a settlement involving Dr. Reddy’s Laboratories partly offsetting earlier restructuring and regulatory-related expenses. For FY26 as a whole, Wockhardt reported a profit after tax of ₹199 crore, a marked improvement from a loss of ₹57 crore in FY25—its first full-year profit in recent years. Revenue for the year rose 11% to ₹3,373 crore. EBITDA jumped 51% to ₹630 crore, with margins expanding to 18.7% from 13.8% a year earlier.